vs

Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and NATIONAL PRESTO INDUSTRIES INC (NPK). Click either name above to swap in a different company.

Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $164.0M, roughly 1.2× NATIONAL PRESTO INDUSTRIES INC). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 21.7%). NATIONAL PRESTO INDUSTRIES INC produced more free cash flow last quarter ($12.4M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 46.3%).

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

National Presto Industries is a company founded in 1905 in Eau Claire, Wisconsin. Originally called "Northwestern Steel and Iron Works" the company changed its name to the "National Pressure Cooker Company" in 1929 and then National Presto Industries, Inc. 1953. The company originally produced pressure canners for commercial, and later home, use. Beginning in 1939, the company introduced small home-use cooking appliances. The company was admitted to the New York Stock Exchange on March 3, 1969.

AXSM vs NPK — Head-to-Head

Bigger by revenue
AXSM
AXSM
1.2× larger
AXSM
$196.0M
$164.0M
NPK
Growing faster (revenue YoY)
AXSM
AXSM
+43.3% gap
AXSM
65.0%
21.7%
NPK
More free cash flow
NPK
NPK
$31.2M more FCF
NPK
$12.4M
$-18.7M
AXSM
Faster 2-yr revenue CAGR
AXSM
AXSM
Annualised
AXSM
61.7%
46.3%
NPK

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AXSM
AXSM
NPK
NPK
Revenue
$196.0M
$164.0M
Net Profit
$-28.6M
Gross Margin
16.9%
Operating Margin
-13.8%
11.4%
Net Margin
-14.6%
Revenue YoY
65.0%
21.7%
Net Profit YoY
61.9%
EPS (diluted)
$-0.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXSM
AXSM
NPK
NPK
Q4 25
$196.0M
$164.0M
Q3 25
$171.0M
$115.5M
Q2 25
$150.0M
$120.4M
Q1 25
$121.5M
$103.6M
Q4 24
$118.8M
$134.7M
Q3 24
$104.8M
$91.8M
Q2 24
$87.2M
$85.1M
Q1 24
$75.0M
$76.7M
Net Profit
AXSM
AXSM
NPK
NPK
Q4 25
$-28.6M
Q3 25
$-47.2M
$5.3M
Q2 25
$-48.0M
$5.2M
Q1 25
$-59.4M
$7.6M
Q4 24
$-74.9M
Q3 24
$-64.6M
$8.1M
Q2 24
$-79.3M
$6.1M
Q1 24
$-68.4M
$6.6M
Gross Margin
AXSM
AXSM
NPK
NPK
Q4 25
16.9%
Q3 25
13.9%
Q2 25
15.4%
Q1 25
17.5%
Q4 24
24.3%
Q3 24
18.8%
Q2 24
17.3%
Q1 24
18.1%
Operating Margin
AXSM
AXSM
NPK
NPK
Q4 25
-13.8%
11.4%
Q3 25
-27.0%
5.6%
Q2 25
-24.5%
5.1%
Q1 25
-46.9%
8.8%
Q4 24
-61.1%
17.3%
Q3 24
-59.8%
10.0%
Q2 24
-89.5%
7.5%
Q1 24
-89.7%
8.2%
Net Margin
AXSM
AXSM
NPK
NPK
Q4 25
-14.6%
Q3 25
-27.6%
4.6%
Q2 25
-32.0%
4.3%
Q1 25
-48.9%
7.3%
Q4 24
-63.1%
Q3 24
-61.7%
8.8%
Q2 24
-91.0%
7.1%
Q1 24
-91.1%
8.6%
EPS (diluted)
AXSM
AXSM
NPK
NPK
Q4 25
$-0.55
Q3 25
$-0.94
Q2 25
$-0.97
Q1 25
$-1.22
Q4 24
$-1.54
Q3 24
$-1.34
Q2 24
$-1.67
Q1 24
$-1.44

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXSM
AXSM
NPK
NPK
Cash + ST InvestmentsLiquidity on hand
$322.9M
$3.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$88.3M
$395.1M
Total Assets
$689.8M
$500.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXSM
AXSM
NPK
NPK
Q4 25
$322.9M
$3.8M
Q3 25
$325.3M
$4.6M
Q2 25
$303.0M
$4.8M
Q1 25
$300.9M
$5.5M
Q4 24
$315.4M
$22.7M
Q3 24
$327.3M
$33.2M
Q2 24
$315.7M
$53.4M
Q1 24
$331.4M
$87.9M
Stockholders' Equity
AXSM
AXSM
NPK
NPK
Q4 25
$88.3M
$395.1M
Q3 25
$73.7M
$379.8M
Q2 25
$73.1M
$374.1M
Q1 25
$53.2M
$368.6M
Q4 24
$57.0M
$367.6M
Q3 24
$92.9M
$346.6M
Q2 24
$102.9M
$338.1M
Q1 24
$144.0M
$331.6M
Total Assets
AXSM
AXSM
NPK
NPK
Q4 25
$689.8M
$500.7M
Q3 25
$669.3M
$503.8M
Q2 25
$639.8M
$471.9M
Q1 25
$596.7M
$455.3M
Q4 24
$568.5M
$453.4M
Q3 24
$561.5M
$428.9M
Q2 24
$548.2M
$418.1M
Q1 24
$545.7M
$417.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXSM
AXSM
NPK
NPK
Operating Cash FlowLast quarter
$-18.7M
$13.9M
Free Cash FlowOCF − Capex
$-18.7M
$12.4M
FCF MarginFCF / Revenue
-9.6%
7.6%
Capex IntensityCapex / Revenue
0.0%
0.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-93.9M
$-36.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXSM
AXSM
NPK
NPK
Q4 25
$-18.7M
$13.9M
Q3 25
$1.0M
$-24.6M
Q2 25
$-32.4M
$-10.9M
Q1 25
$-43.4M
$12.5M
Q4 24
$-26.2M
$-7.6M
Q3 24
$-18.6M
$-17.5M
Q2 24
$-30.1M
$-33.9M
Q1 24
$-53.5M
$5.6M
Free Cash Flow
AXSM
AXSM
NPK
NPK
Q4 25
$-18.7M
$12.4M
Q3 25
$988.0K
$-24.7M
Q2 25
$-32.4M
$-13.4M
Q1 25
$-43.7M
$-10.5M
Q4 24
$-26.2M
$-11.3M
Q3 24
$-18.7M
$-20.3M
Q2 24
$-30.2M
$-34.5M
Q1 24
$-53.6M
$5.2M
FCF Margin
AXSM
AXSM
NPK
NPK
Q4 25
-9.6%
7.6%
Q3 25
0.6%
-21.4%
Q2 25
-21.6%
-11.1%
Q1 25
-36.0%
-10.2%
Q4 24
-22.1%
-8.4%
Q3 24
-17.9%
-22.1%
Q2 24
-34.6%
-40.6%
Q1 24
-71.4%
6.7%
Capex Intensity
AXSM
AXSM
NPK
NPK
Q4 25
0.0%
0.9%
Q3 25
0.0%
0.1%
Q2 25
0.0%
2.0%
Q1 25
0.3%
22.2%
Q4 24
0.0%
2.7%
Q3 24
0.1%
3.1%
Q2 24
0.1%
0.8%
Q1 24
0.1%
0.5%
Cash Conversion
AXSM
AXSM
NPK
NPK
Q4 25
Q3 25
-4.63×
Q2 25
-2.12×
Q1 25
1.64×
Q4 24
Q3 24
-2.16×
Q2 24
-5.58×
Q1 24
0.85×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons